All In Biotech

Drug Trial Radar · NCT01606345

Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma

Phase I Dose Escalation and Landmark Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma (UTUC) Following Endoscopic Resection

Last checked: Nov 20, 2026Latest source record: Apr 22, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

4

Actual

Start

Jul 2012

Primary completion

Apr 2016

Study completion Apr 2016

Sponsor

Lead sponsor
H. Lee Moffitt Cancer Center and Research InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Endo USA Inc., a Keenova Therapeutics Company
First posted
May 25, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn more about how well the drug valrubicin (VALSTAR®) works to help treat the patient's cancer when administered through a nephrostomy tube inserted through their back into their kidney. The study is also being done to determine how safe and easy it is to tolerate valrubicin at specific dose levels, as well as the way in which the drug is eliminated from the human body (Pharmacokinetics or PK).

Conditions

  • Urothelial Carcinoma

Interventions

  • ValrubicinDrug

    Eligible patients will receive percutaneous valrubicin beginning no sooner than 10 days following nephrostomy placement and within 6 weeks of tumor treatment/resection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerated Dose (MTD)Time frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • H. Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.